window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : February 3, 2026

  • News
  • About Us
Contact Us

Huntington’s disease

  • Central Nervous System,Clinical Trials,Drug Development,Rare Diseases,Research & Development

    Skyhawk Therapeutics reports positive nine-month interim results for SKY-0515 in Huntington’s disease

    Skyhawk Therapeutics has reported positive nine-month interim results from its [...]

    January 29, 2026
  • Cell & Gene Therapy,Central Nervous System,Clinical Trials,Neurosciences,Pharmaceuticals and therapeutics,Research & Development

    Gene therapy AMT-130 slows Huntington’s disease progression in early trial

    A gene therapy developed by uniQure appears to slow progression [...]

    September 25, 2025
  • Drug Development,Neurosciences,Rare Diseases,Regulatory Affairs

    SOM Biotech secures EMA orphan designation opinion for Huntington’s drug SOM3355

    Barcelona-based biotech advances Huntington’s programme as EMA backs orphan designation, [...]

    September 15, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Skyhawk Therapeutics reports positive nine-month interim results for SKY-0515 in Huntington’s disease
    Categories: Central Nervous System, Clinical Trials, Drug Development, Rare Diseases, Research & Development
  • iOrganBio appoints Karol Jarzabek as chief operating officer
    Categories: Biologics & Biosimilars, Cell & Gene Therapy, Healthcare leadership, Manufacturing, Movers & Shakers, Pharmaceuticals and therapeutics
  • iXCells Biotechnologies partners with Rosebud Biosciences to advance organoid models for rare diseases
    Categories: Biologics & Biosimilars, Cell & Gene Therapy, Clinical Development, Drug Development, Rare Diseases, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top